Revelation Biosciences, Inc. Price & Performance (REVB)

Revelation Biosciences shares dropped 10.77% to $2.86 in recent trading, with the company’s market cap now at $2.5 million. The decline follows a broader trend of investor disinterest in small-cap biopharma stocks lacking new developments, further pressuring REVB after a 13% loss earlier this month.12

GRI Bio’s short interest soared 281.8% as of mid-April, with 34.61% of its float now sold short. This spike signals increasing negative sentiment among investors, placing GRI Bio among the most shorted pharmaceutical stocks and highlighting broader volatility in the sector.3

Recent days have seen a flurry of corporate actions, including delistings and reverse splits. Notably, Cara Therapeutics executed a 1-for-3 reverse split, while several companies like MoneyLion and Enfusion were delisted pending liquidation. These moves underscore ongoing instability in the small-cap health sector.4